Targeted next-generation sequencing of DNA is now the standard of care for management of patients with lung adenocarcinoma, with the goal of identifying actionable genomic alterations that may guide choice of therapy. Predictive biomarkers in the setting of non–small cell lung cancer (NSCLC) include gene fusions in tumors that have rearranged during transfection (RET). In NSCLC, chromosomal rearrangements between the RET gene and another domain lead to overexpression of the RET protein. These gene fusions have been identified as oncogenic drivers in multiple tumor types. They have the potential to cause chimeric, cytosolic proteins with constitutively active RET kinase domain, leading to increased cell proliferation, migration, and survival.
How familiar are you with RET rearrangements in NSCLC? Test your knowledge with this quick quiz.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation - Medscape - Aug 24, 2021.